UnitedHealthcare Sued for $100M Medicaid Fraud on May 31

Massachusetts sued UnitedHealthcare on May 29, claiming the company defrauded the state’s Medicaid program by making seniors appear sicker than they were. The lawsuit alleges $100 million in fraudulent overbilling through a scheme that ran from 2015 to 2025. UnitedHealthcare stock fell 0.58% to $380.31 on May 31 as investors weighed the legal risk.

How the Alleged Scheme Worked

UnitedHealthcare contracted with MassHealth to provide Senior Care Options, combining Medicare and Medicaid benefits for seniors aged 65 and older. The lawsuit alleges the company used fraudulent diagnoses to boost reimbursements tied to patients enrolled in both programs. Internal reviews conducted in 2018 and 2019 reportedly flagged the practice, but the company did not correct it.

What This Means for the Stock

Meyka rates UnitedHealthcare a B+ with a 12-month price target of $457.16, suggesting 20% upside from current levels. However, 38 analysts rate the stock a Buy while only 1 rates it a Sell, indicating broad confidence despite the lawsuit. The stock trades at a P/E of 28.65, above the sector average, leaving limited margin for error if legal costs mount.

Broader Medicaid Fraud Trend

UnitedHealthcare’s case is not isolated. A New Windsor couple admitted to stealing $3.4 million from New York’s Medicaid program through fake transportation billing between 2020 and 2024. These cases reflect growing scrutiny of Medicaid providers and state efforts to recover overbilled funds.

Financial Impact and Next Steps

The lawsuit seeks recovery of the $100 million plus penalties. UnitedHealthcare’s market cap stands at $345.3 billion, so a single settlement would not threaten solvency. However, regulatory action could trigger additional investigations and settlements across other state programs, raising long-term compliance costs.

Final Thoughts

Massachusetts’ $100 million fraud claim against UnitedHealthcare highlights regulatory risk in the health insurance sector. With Meyka rating the stock B+ and analysts favoring it, the market has priced in modest legal exposure, but sustained investigations could pressure earnings.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.